Rapport Therapeutics, Inc. director James Healy buys $20.4M in stock
After the purchase, the filing lists 2,873,888 shares held.
James Healy purchased about $20 million of Rapport Therapeutics, Inc. (RAPP) stock on Oct 28, according to an SEC filing. The director paid an average of $21.00 for 969,480 shares.
The purchase was made in the open market, not through an award, an option exercise or a plan. Other Rapport Therapeutics, Inc. insiders have also bought: Six insiders made open-market purchases within 14 days, a pattern known as a cluster buy.
With this purchase the insider holds 2,873,888 shares, 51% more than before. The trade was reported within two business days, as Section 16 requires.
Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.
| Company | Rapport Therapeutics, Inc. (RAPP) |
|---|---|
| Insider | James Healy |
| Role | Director |
| Transaction | Open-market purchase (code P) |
| Shares | 969,480 |
| Average price | $21.00 |
| Value | $20,359,080 |
| Trade date | Oct 28, 2026 |
| Filed with the SEC | Oct 30, 2026, 7:32 PM ET |
| Shares held after | 2,873,888 |
| Ownership | Indirect |
| Rule 10b5-1 plan | Not marked in the filing |
See the full details of this insider trade
See where several insiders traded together · Browse the insider trading newsroom
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.